Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624330 | 1.00 | USP30 (0.62) | USP30HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL4013907 | 0.91 | USP30 (0.54) | USP30HSD11B1JAK2JAK1HPGD | |
| SCHEMBL4020310 | 0.91 | USP30 (0.54) | USP30HSD11B1JAK2JAK1HPGD | |
| SCHEMBL4014859 | 0.91 | USP30 (0.54) | USP30HSD11B1JAK2JAK1HPGD | |
| SCHEMBL1780697 | 0.88 | USP30 (0.59) | USP30HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL13934774 | 0.88 | USP30 (0.59) | USP30HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL14331976 | 0.88 | USP30 (0.59) | USP30HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL21285788 | 0.88 | HSD11B1 (0.69) | USP30HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL654494 | 0.87 | USP30 (0.58) | USP30HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL21782989 | 0.87 | USP30 (0.58) | USP30HSD11B1JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-17 | — | — | US | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | USP30 3809/4885HSD11B1 4751/4885JAK2 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.